vs
Apellis Pharmaceuticals, Inc.（APLS）与PEOPLES BANCORP INC（PEBO）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是PEOPLES BANCORP INC的1.7倍（$199.9M vs $118.7M），PEOPLES BANCORP INC净利率更高（24.4% vs -29.5%，领先53.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
该公司是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，同时也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构。它主营银行、投资、抵押贷款等相关金融业务。
APLS vs PEBO — 直观对比
营收规模更大
APLS
是对方的1.7倍
$118.7M
净利率更高
PEBO
高出53.9%
-29.5%
两年增速更快
APLS
近两年复合增速
3.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $118.7M |
| 净利润 | $-59.0M | $29.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 24.4% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | -8.7% |
| 每股收益（稀释后） | $-0.40 | $0.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPEBO
| Q1 26 | — | $118.7M | ||
| Q4 25 | $199.9M | $117.3M | ||
| Q3 25 | $458.6M | $115.2M | ||
| Q2 25 | $178.5M | $114.5M | ||
| Q1 25 | $166.8M | $112.4M | ||
| Q4 24 | $212.5M | $111.6M | ||
| Q3 24 | $196.8M | $113.7M | ||
| Q2 24 | $199.7M | $110.3M |
净利润APLSPEBO
| Q1 26 | — | $29.0M | ||
| Q4 25 | $-59.0M | $31.8M | ||
| Q3 25 | $215.7M | $29.5M | ||
| Q2 25 | $-42.2M | $21.2M | ||
| Q1 25 | $-92.2M | $24.3M | ||
| Q4 24 | $-36.4M | $26.9M | ||
| Q3 24 | $-57.4M | $31.7M | ||
| Q2 24 | $-37.7M | $29.0M |
营业利润率APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 32.4% | ||
| Q3 25 | 48.7% | 33.0% | ||
| Q2 25 | -18.6% | 24.0% | ||
| Q1 25 | -50.0% | 27.9% | ||
| Q4 24 | -12.3% | 31.2% | ||
| Q3 24 | -24.0% | 36.0% | ||
| Q2 24 | -14.7% | 32.5% |
净利率APLSPEBO
| Q1 26 | — | 24.4% | ||
| Q4 25 | -29.5% | 27.1% | ||
| Q3 25 | 47.0% | 25.6% | ||
| Q2 25 | -23.6% | 18.5% | ||
| Q1 25 | -55.3% | 21.7% | ||
| Q4 24 | -17.1% | 24.1% | ||
| Q3 24 | -29.2% | 27.9% | ||
| Q2 24 | -18.9% | 26.3% |
每股收益（稀释后）APLSPEBO
| Q1 26 | — | $0.81 | ||
| Q4 25 | $-0.40 | $0.89 | ||
| Q3 25 | $1.67 | $0.83 | ||
| Q2 25 | $-0.33 | $0.59 | ||
| Q1 25 | $-0.74 | $0.68 | ||
| Q4 24 | $-0.30 | $0.76 | ||
| Q3 24 | $-0.46 | $0.89 | ||
| Q2 24 | $-0.30 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $82.9M |
| 总债务越低越好 | — | $691.3M |
| 股东权益账面价值 | $370.1M | $1.2B |
| 总资产 | $1.1B | $9.6B |
| 负债/权益比越低杠杆越低 | — | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资APLSPEBO
| Q1 26 | — | $82.9M | ||
| Q4 25 | $466.2M | $189.0M | ||
| Q3 25 | $479.2M | $190.2M | ||
| Q2 25 | $370.0M | $186.1M | ||
| Q1 25 | $358.4M | $187.0M | ||
| Q4 24 | $411.3M | $217.7M | ||
| Q3 24 | $396.9M | $283.7M | ||
| Q2 24 | $360.1M | $235.9M |
总债务APLSPEBO
| Q1 26 | — | $691.3M | ||
| Q4 25 | — | $204.1M | ||
| Q3 25 | — | $227.3M | ||
| Q2 25 | — | $232.4M | ||
| Q1 25 | — | $237.0M | ||
| Q4 24 | — | $238.1M | ||
| Q3 24 | — | $236.8M | ||
| Q2 24 | — | $234.3M |
股东权益APLSPEBO
| Q1 26 | — | $1.2B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.1B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.1B |
总资产APLSPEBO
| Q1 26 | — | $9.6B | ||
| Q4 25 | $1.1B | $9.6B | ||
| Q3 25 | $1.1B | $9.6B | ||
| Q2 25 | $821.4M | $9.5B | ||
| Q1 25 | $807.3M | $9.2B | ||
| Q4 24 | $885.1M | $9.3B | ||
| Q3 24 | $901.9M | $9.1B | ||
| Q2 24 | $904.5M | $9.2B |
负债/权益比APLSPEBO
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.20× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $134.7M | ||
| Q3 25 | $108.5M | $14.4M | ||
| Q2 25 | $4.4M | $50.7M | ||
| Q1 25 | $-53.4M | $34.3M | ||
| Q4 24 | $19.4M | $143.2M | ||
| Q3 24 | $34.1M | $34.1M | ||
| Q2 24 | $-8.3M | $32.1M |
自由现金流APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $128.7M | ||
| Q3 25 | $108.3M | $12.7M | ||
| Q2 25 | $4.4M | $49.2M | ||
| Q1 25 | $-53.4M | $31.5M | ||
| Q4 24 | $19.3M | $136.4M | ||
| Q3 24 | — | $33.2M | ||
| Q2 24 | $-8.4M | $30.2M |
自由现金流率APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 109.7% | ||
| Q3 25 | 23.6% | 11.0% | ||
| Q2 25 | 2.5% | 43.0% | ||
| Q1 25 | -32.0% | 28.1% | ||
| Q4 24 | 9.1% | 122.2% | ||
| Q3 24 | — | 29.2% | ||
| Q2 24 | -4.2% | 27.4% |
资本支出强度APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 5.1% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 1.3% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 6.1% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 1.7% |
现金转化率APLSPEBO
| Q1 26 | — | — | ||
| Q4 25 | — | 4.24× | ||
| Q3 25 | 0.50× | 0.49× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 5.32× | ||
| Q3 24 | — | 1.08× | ||
| Q2 24 | — | 1.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PEBO
| Net Interest Income | $90.4M | 76% |
| Noninterest Income | $28.3M | 24% |
